Skip to main content

Drug Interactions between moexipril and Salonpas

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

capsaicin topical moexipril

Applies to: Salonpas (capsaicin / menthol topical) and moexipril

Concomitant use of ACE inhibitors and capsaicinoid topical products may potentiate the cough associated with these agents individually. In 16 healthy volunteers, pretreatment with oral captopril (25 mg) two hours before inhalation of nebulized incremental doses of capsaicin (0.5 to 20 micromol/L in normal saline) resulted in a significant shift of the dose-response curve to capsaicin compared to pretreatment with placebo. The geometric mean dose of capsaicin causing 20 coughs per minute was 1.3 micromol/L for captopril and 2.8 micromol/L for placebo. In a case report, a 53-year-old woman who had been treated with an ACE inhibitor for several years complained of cough each time she applied a 0.075% capsaicin cream to her lower extremities. The patient had not experienced a cough during treatment with the ACE inhibitor alone. However, capsaicin alone may also induce coughing.

References (2)
  1. Morice AH, Brown MJ, Lowry R, Higenbottam T (1987) "Angiotensin-converting enzyme and the cough reflex." Lancet, 2, p. 1116-8
  2. Hakas JF Jr (1990) "Topical capsaicin induces cough in patient receiving ACE inhibitor." Ann Allergy, 65, p. 322-3

Switch to consumer interaction data

Drug and food interactions

Moderate

moexipril food

Applies to: moexipril

GENERALLY AVOID: Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors. In some cases, affected patients were using a potassium-rich salt substitute. ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.

MANAGEMENT: It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake. Particular attention should be paid to the potassium content of salt substitutes.

References (3)
  1. (2002) "Product Information. Vasotec (enalapril)." Merck & Co., Inc
  2. Good CB, McDermott L (1995) "Diet and serum potassium in patients on ACE inhibitors." JAMA, 274, p. 538
  3. Ray K, Dorman S, Watson R (1999) "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens, 13, p. 717-20

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer